499 related articles for article (PubMed ID: 25189729)
1. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
2. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
3. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
4. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
5. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
6. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of pacritinib in myelofibrosis.
Verstovsek S; Komrokji RS
Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
[TBL] [Abstract][Full Text] [Related]
8. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
9. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
11. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
12. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Santos FP; Verstovsek S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
[TBL] [Abstract][Full Text] [Related]
13. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
14. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
15. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
18. New Concepts of Treatment for Patients with Myelofibrosis.
Bose P; Alfayez M; Verstovsek S
Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
[TBL] [Abstract][Full Text] [Related]
19. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Jain T; Mesa R
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
[TBL] [Abstract][Full Text] [Related]
20. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]